Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen For The Treatment Of Hypertensive Disorders Of Pregnancy, Including Preeclampsia
September 12, 2014 at 08:02 AM EDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is broadening its pipeline ...
